Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to initiate a Phase 3 Clinical Trial of intralesional rhEGF for the treatment of diabetic foot ulcers FDA approves Discovery Therapeutic Caribe's Phase 3 trial for intralesional rhEGF in severe diabetic foot ulcers.